Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Monte Rosa Therapeutics, Inc.
| Metric | Monte Rosa Therapeutics, Inc. GLUEHealthcare |
|---|---|
| Quality Score | 55 / 100 |
| Revenue (latest) | $124M |
| Net income (latest) | −$39M |
| Operating margin | −43.8% |
| Net margin | −31.2% |
| Return on equity | −16.6% |
| Return on assets | −8.6% |
| Return on capital (ROCE) | −14.1% |
| Debt / equity | 0.93× |
| Revenue growth (YoY) | 63.5% |
| Altman Z″ (distress) | 1.67 |
| Accruals / assets | −3.5% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.